DAWN News

Six IPOs raised $1.8 billion ahead of the short holiday week, joined by one direct listing and five SPACs. Returns bounced back after tumultuous trading earlier this month, with the week’s deals all finishing above issue. New filers began to flood the summer IPO pipeline, with 19 IPOs and eight SPACs submitting initial filings. Healthcare apparel brand FIGS...read more

Day One Biopharmaceuticals, a Phase 2 biotech developing kinase inhibitors for pediatric brain tumors, raised $160 million by offering 10 million shares at $16, the high end of the range of $14 to $16. The company originally planned to offer 8.4 million shares at the same range, before revising the terms on Wednesday morning. At pricing, the company commands a market value of $965...read more

Day One Biopharmaceuticals, a Phase 2 biotech developing kinase inhibitors for pediatric brain tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The South San Francisco, CA-based company now plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. The company had previously filed to offer 8.4 million shares at the same...read more

Day One Biopharmaceuticals, a Phase 2 biotech developing treatments for pediatric glioma and other cancers, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $126 million by offering 8.4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Day One Biopharmaceuticals would command a market value of...read more